ANGPTL4 suppresses progression and improves cisplatin sensitivity in cervical cancer
Issued Date
2025-12-01
Resource Type
eISSN
20452322
Scopus ID
2-s2.0-105003272404
Journal Title
Scientific Reports
Volume
15
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Scientific Reports Vol.15 No.1 (2025)
Suggested Citation
Chan-on W., Turinthorn M., Chaiwongkot A., Techawiwattanaboon T., Khaenam P., Leepiyasakulchai C. ANGPTL4 suppresses progression and improves cisplatin sensitivity in cervical cancer. Scientific Reports Vol.15 No.1 (2025). doi:10.1038/s41598-025-99136-z Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/109892
Title
ANGPTL4 suppresses progression and improves cisplatin sensitivity in cervical cancer
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Cervical cancer (CC) remains a leading cause of cancer-related deaths worldwide and still requires effective interventions to improve patient outcomes. Angiopoietin-like 4 (ANGPTL4) is a multifaceted glycoprotein that plays crucial roles in lipid metabolism and tumor progression. ANGPTL4 exhibits both tumor-promoting and tumor-suppressing effects and has been proposed as a promising target for cancer therapy. This study investigated the role and potential of ANGPTL4 in enhancing therapeutic efficacy in CC using cell line models in vitro. Our analysis revealed a decreased expression of ANGPTL4 in CC samples from the GSE dataset and in the CC cell lines examined. Functional assays demonstrated that ANGPTL4 overexpression suppressed CC cell proliferation, migration, and invasion. Notably, overexpression of ANGPTL4 resulted in decreased cell viability and increased levels of apoptosis, cleaved caspase-3, and cleaved PARP under cisplatin treatment. Furthermore, these analyses were also conducted in ANGPTL4-knockdown cells, and results supporting the tumor-suppressive roles of ANGPTL4 were observed. Taken together, our study elucidates the critical role of ANGPTL4 in modulating progression and chemosensitivity of CC cells, suggesting ANGPTL4 as a potential target for CC treatment.